Pfizer Canada is exploring public-private partnerships and open innovation models to address gaps in drug innovation. These models include pre-competitive research partnerships and consortia involving multiple companies, universities, and research institutions. They aim to leverage diverse scientific capabilities and resources to make progress on understanding disease biology and developing new treatments. By sharing knowledge and resources in a pre-competitive space, these partnerships seek to accelerate innovation for the benefit of patients while also engaging industry, academia and government.

2. Pfizer Canada
To Be Truly Healthy,
It Takes More Than Medication

3. Innovation Gap

4. Innovation Gap
! “We intend to make our internal capability even more effective by tapping
into the best scientific capability outside of our walls -wherever it exists.
That’s why we are reaching out to scientists around the world.”
Jeff Kindler, CEO, Pfizer

6. Understanding Disease Biology is not a
Competitive Activity

7. Canadian Public-Private Partnership Models
of Innovation
Pre-Competitive Partnership Models of Innovation Competitive
Collaborative R&D Partnerships
Centers of Excellence in Commercialization (CECRs)
Quebec Pain Research Network (QPRN)
Ontario Institute of Cancer Research (OICR)
Center for Drug Research & Discovery (CDRD)
Pre-Competitive R&D Partnerships
Quebec Drug Discovery Consortium (CQDM)
Structural Genomics Consortium (SGC)

8. Canadian Public-Private Partnership Models
of Innovation
World class science drives the day……
Very significant internal competition for global R&D $$s
Local affiliates can drive internal global recognition of local
opportunities, through local resources and local funds.
Alignment with large consortia and public funding is very
helpful
IRMA : THE DRUG In the Future
REPOSITIONING
INITIATIVE Public-Private and Pre-competitive research is growing
ON is in position to excel in this emerging paradigm
Public support of PPP is not a temporary concept. Funding
must be maintained, as a basis for attracting other $$s into
the project.

9. Enable Integrate Engage
A New Model for the Translation of Regenerative Medicine:
Collaborative, Capital-Efficient Technology Development
New Models of Innovation in Life Sciences
April 20th, 2011, MaRS, Toronto
Michael H. May PhD
CEO
Slide 1

10. “Open Innovation” is Not New
Open
Collaboration
Innovation
Non-Zero-Sum
Gain
Technology
Zero-Sum
Gain
Environmental
Stress or Need Competition
“NONZERO – The Logic of Human Destiny”, Robert Wright
Slide 2

11. Funding of Research and
Commercialization in Canada
Slide 3

12. CCRM Builds on MaRS and MI
!"#$%&'()'*%&#+!#,-..-*%#
/%%)/..0#*%#123#
Slide 4

13. A Global Nexus for RM Technology
and Commercialization
Mission: To bridge the RM commercialization
gap by leveraging funding and infrastructure,
and mobilizing business and scientific
expertise to translate technologies
Existing Industry
Government Investment
Programs Capital
Pre- Clinical &
Product
Basic R&D Commercial Commercial
Development
Validation Validation
Slide 5

14. Our Plan to Bridge the RM
Commercialization Gap
Existing Industry
Government Investment
Programs Capital
Enable Product Integrate Science and Create Links
Development Business to Market
Slide 6

15. Translation through Collaboration
Slide 7

16. capital efficient RM development
utilize academic infrastructure
facilitate global collaboration
focus on key bottlenecks
explore alternative funding sources
Slide 8

17. Slide 9

18. Industry Engagement
Platform 1 Platform 2 Platform 3
4 companies, 2 6 companies, 2 6 companies, 2
Canadian, 2 large Canadian, 3 large Canadian, 1 large
and 3 small and 3 small and 5 small
Community Offerings Market Needs
! iPSC cells
! Lineage reprogramming Characterized and validated
! Stem cell characterization stem cell lines
and standardization
Clinical and commercial
! Cell culture bioprocesses,
quantities of stem/differentiated
sensors and scale-up / out
cells
! Biomaterials/biocompatibility
! Therapeutic polymers Tissue mimetics for drug
! Microfabrication screening & transplantation
! Functional and stabilized,
cell-derived tissues Foundational Reagents, tools
and processes Slide 10

19. Driving Open Innovation
Collaboration
Non-Zero-Sum
Gain
" Capital efficient
Technology " Pre-competitive
Zero-Sum
Gain
Environmental
Stress or Need
Slide 11

20. evidence-based infection control

21. Evidence-based Infection Control!
#$%"&'(')*+",-./0')$%"1%'0-*"'*2-34)*"3)*5%)6"$('*7"7-)(8/4/6"/*/6943(:"5)";)*'5)%:"
;-/($%-:"/*1"';8%)0-")$53);-(<"
#$%"=)/6+">-68"/3.'-0-"/*1"-?3--1"8/4-*5"(/2-59"';8-%/40-("@"8%')%'4-("
A"B-/%("C$;$6/40-"D-/%*'*7+"E'(-/(-"($%0-'66/*3-"/*1"'*2-34)*"3)*5%)6"()6$4)*(<"
F "G)()3);'/6"3/(-";/*/7-;-*5"
F "H$5);/5-1"./*1".97'-*-"3);86'/*3-";)*'5)%'*7"
F "H$5);/5-1")$5I%-/J"3)*5/35"5%/3'*7""
F "K>)5L(8)5M"'1-*4N3/4)*"
F "O-/6L4;-"@"($(5/'*-1"5%/3J'*7:"/6-%5("@";-5%'3("
!"

22. Innovation in Healthcare...!
Incremental innovation tends to be ‘evolutionary’.
Small improvements in existing practices.!
Disruptive innovation improves a product or service
in ways that the market does not expect and looks to
make significant impacts.!
Goal in healthcare is affordability/sustainability while
increasing accessibility, quality and safety. This sector
should be an ideal target for disruptive solutions.!
3

23. Open Innovation!
• C)*0-%7-*3-"Q)6$4)*"
• R/%5*-%("S'5."H6'7*-1"=)/6("
• C)*N%;"&'(')*"/*1"R/5."
• T/'*5/'*"5.-"&'()*"
• =-5M-%"E)*-"
P"

24. !"#$%&"'()*+",-"./&-"0--,1$2,-"
34&"'5#"

25. '5#6",/&-"$77&%%"%70&-7&"
• 8,9:&*"0-";<<="(,">&-&9$(&"?-,@A&*>&"$B,)("4):$-"/9,(&0-%"
• C&%)A(%"$-*"9&$>&-(%"0-(,"/)BA07"*,:$0-"@0(4,)("9&%(9072,-"
• D,"-,("EA&"F,9"GH",-"$-+"9&%)A(%"
• =<I",F">A,B$A",)(/)(",F"-&@"4):$-"$-*"/$9$%0(&"/9,(&0-"%(9)7()9&%"
• ;"/$/&9%"/&9"@&&?"

26. !"/)BA07J/901$(&"/$9(-&9%40/"
'@&*&-"
H4$9:$"
#$-$*$"
.-($90,"
K&AA7,:&"39)%("

27. Industrial focus yields HQP
Former SGC members:
• > 65 scientists went on to jobs in academia
• 15 to leadership positions (7 Faculty positions)
• > 33 to industry (9 to leadership positions)
• 7 returned to the SGC/or relocated to another SGC site
• 4 to business schools
Training at SGC:
• 187 external scientists trained at the SGC (20 coop students)

28. No IP facilitates collaboration
• More than 200 Collaborations in 17 countries world wide
• ~250 publications – an average of 3.1 non-SGC scientists per paper
1 collaboration
2-5 collaborations
>1000 expression clones have been sent 5-10 collaborations
out during the past 3 years of which more 10-20 collaborations
than 800 to academia
> 20 collaborations

29. Knowledge transfer
• Over the last 3 years SGC scientists attended >250 conferences the
majority of them as speakers
• Serve on SAB s of 5 biotech companies; 3 research consortia and 2 funding
agencies
• The SGC organised 20 workshops/conferences during the past three years
• More than 50 face-to-face meetings with industry per year
• More than 100 external scientists attended workshops held at SGC

30. Technology development
SGC driven developments:
! Lex System
! BeeHive (w. MolSoft, Inovacia, CPR)
! iSee (MolSoft)
! Software for domain boundary analysis
! Expression clone generating platform
! Phage-resistant bacterial host strains
! Proximity assay!
Testing and Improvement of a number of different products/
machines in collaboration with vendors:
Crystallisation:
! JCSG+ crystallization screen
! Mosquito crystallization robot
! Minstrel imaging robot
! Actor anti-icing lid
! SpearLab Liquid nitrogen handling dewars
Compound screening
! Stratagene/Agilent RT-PCR
! Stargazer
! BMG Labtech multi-functional plate reader "Polarstar Omega“
! Biacore with GE Healthcare
Other
! Contur ELN

31. Commercialization
Harbinger Biotech, founded in 2005, has sold equipment to over
30 labs in industry and academia in Asia, North America and
Europe
SGC software programs distributed to >40 labs
1DegreeBio founded in 2010

32. Moving the Pre-Competitive Boundary
H)BA07LH901$(&" H)BA07"
G-*)%(9+"
H$9(-&9%40/" D,:$0-"
Chemical Target Drug
Probes Validation Discovery
Screening No IP (re)Screening
Chemistry No restrictions Chemistry
Structure Publication Lead optimization
Bioavailability Pharmacology
DMPK
Toxicology
Chemical development
Clinical development
Creative commons Proprietary

33. Impact of novel BET probe
250+ labs
across
the globe
Identified Published Distributed
Jan 10 Sep 10 Jan 11